Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy

T Morelli, K Fujita, G Redelman-Sidi, PT Elkington - Thorax, 2022 - thorax.bmj.com
Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment. However, immune-
related adverse events (irAEs) are a common side effect which can mimic infection …

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update

BJ Schneider, J Naidoo, BD Santomasso… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Effect of COVID-19 on lungs: focusing on prospective malignant phenotypes

P Sadhukhan, MT Ugurlu, MO Hoque - Cancers, 2020 - mdpi.com
Simple Summary According to the coronavirus virus resource center of Johns Hopkins
Medicine, more than 75 million people are presently affected worldwide, including 1.7 …

[HTML][HTML] Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19

M Barnova, A Bobcakova, V Urdova… - Physiological …, 2021 - ncbi.nlm.nih.gov
Summary COVID-19 (Coronavirus Disease) is an infectious disease caused by the
coronavirus SARS-CoV-2 (Severe acute respiratory syndrome Coronavirus 2), which …

Immune checkpoint inhibition in COVID-19: risks and benefits

PS Pezeshki, N Rezaei - Expert Opinion on Biological Therapy, 2021 - Taylor & Francis
Introduction Immune checkpoint inhibition (ICI) is a novel cancer immunotherapy, which is
administered in patients with metastatic, refractory, or relapsed solid cancer types. Since the …

[HTML][HTML] Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review

CJ Yang, YJ Wei, HL Chang, PY Chang… - Journal of Microbiology …, 2021 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral
pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical …

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

M Bersanelli, D Giannarelli… - … in medical oncology, 2020 - journals.sagepub.com
Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the
clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune …

Upregulation of PD‐L1 by SARS‐CoV‐2 promotes immune evasion

HC Huang, SH Wang, GC Fang… - Journal of Medical …, 2023 - Wiley Online Library
Patients with severe COVID‐19 often suffer from lymphopenia, which is linked to T‐cell
sequestration, cytokine storm, and mortality. However, it remains largely unknown how …

Cancer and immune checkpoint inhibitor treatment in the era of SARS-CoV-2 infection

T Gambichler, J Reuther, CH Scheel, L Susok, P Kern… - Cancers, 2020 - mdpi.com
Simple Summary The introduction of immune checkpoint inhibitors (ICI) in 2011
revolutionized the management of many solid cancers and hematological malignancies …

[HTML][HTML] Association of soluble PD-L1 and NLR combination with 1-Year mortality in patients with COVID-19

L Akhmaltdinova, I Mekhantseva, L Turgunova… - International …, 2024 - Elsevier
Purpose Understanding the relationship between patient immune characteristics, disease
severity, and mortality represents a critical step in the fight against COVID-19. Elevated …